SFN (stabilized in alpha-cyclodextrin complex) treatment also inhibited breast CSC activity in primary and metastatic estrogen receptor-positive breast cancer patient-derived samples, seemingly by reducing mammosphere formation efficiency (MFE) and ALDH activity [162]. The gene discussed is ESR1; the disease is breast carcinoma.